euroconferenceworkshop
novel
strategi
mucos
immunis
exploit
mechan
innat
immun
pathogenhost
interact
acronym
innamora
held
siena
novemb
research
centr
chiron
vaccin
aim
meet
implement
european
effort
toward
novel
vaccin
strategi
within
global
vision
mani
object
gather
coordin
relev
eufund
project
vaccin
strategi
mucos
immunis
innat
immun
order
establish
state
art
european
research
field
updat
newest
trend
direct
research
mechan
innat
immun
exploit
design
new
vaccin
strategi
seri
highlevel
overview
lectur
top
scientist
opinion
leader
use
vaccin
gener
introduc
begin
last
centuri
greatli
contribut
abat
incid
seri
infecti
diseas
previous
caus
great
part
mortal
human
popul
vaccin
among
effect
type
medic
intervent
gener
agre
use
caus
caus
disappear
globe
mani
great
killer
past
smallpox
plagu
present
time
rapid
progress
research
continu
increas
public
awar
social
valu
vaccin
set
base
unpreced
favour
situat
implement
vaccin
strategi
worldwid
context
concept
set
forth
world
bank
absenc
health
main
obstacl
econom
develop
poor
countri
place
vaccin
first
action
econom
improv
lessdevelop
countri
likewis
world
health
organis
togeth
unicef
unit
nation
children
fund
launch
global
campaign
immunis
expand
programm
immunis
epi
vaccin
children
worldwid
five
basic
vaccin
polio
diphtheria
measl
pertussi
tetanu
global
allianc
vaccin
immunis
gavi
found
januari
unifi
public
privat
effort
toward
enlarg
vaccin
avail
particularli
lessdevelop
countri
financi
bodi
gavi
vaccin
fund
receiv
excel
support
privat
donat
us
billion
includ
contribut
us
million
bill
melinda
gate
foundat
furthermor
world
econom
forum
held
davo
januari
bill
melinda
gate
foundat
announc
contribut
us
million
establish
grand
challeng
global
health
initi
support
acceler
research
vaccin
develop
aid
malaria
diarrhoeal
diseas
infect
affect
impoverish
countri
main
problem
face
practic
implement
enthusiast
public
privat
initi
progress
disinterest
vaccin
industri
consequ
risk
inadequ
vaccin
suppli
fact
econom
valu
vaccin
neglig
industri
viewpoint
potenti
busi
amount
global
pharmaceut
market
problem
make
vaccin
busi
unattract
compani
includ
high
risk
liabil
action
press
request
humanitarian
organis
decreas
vaccin
price
recalcitr
attitud
public
health
administr
meet
vaccin
cost
full
coverag
popul
consequ
number
industri
produc
manufactur
vaccin
dramat
drop
recent
year
usa
vaccin
compani
decreas
bring
signific
shortag
vaccin
suppli
would
expos
popul
risk
uncontrol
outbreak
vaccineprevent
diseas
even
dramat
would
situat
lessdevelop
countri
vaccin
coverag
need
comprehens
organis
global
effort
toward
vaccin
implement
clearli
need
multipl
level
programm
gavi
similar
programm
need
parallel
clear
polici
toward
encourag
industri
involv
vaccin
research
develop
manufactur
incent
industri
research
invest
vaccin
field
devis
detax
polici
insur
liabil
risk
attract
patent
coverag
waiv
pressur
publicsector
agenc
princip
buyer
vaccin
lower
vaccin
price
without
genuin
involv
vaccin
compani
social
humanitarian
effort
toward
vaccin
lessdevelop
countri
could
hope
success
gener
need
vaccin
develop
countri
involv
vaccin
alreadi
avail
vaccin
still
develop
direct
diseas
affect
develop
countri
interest
industri
case
vaccin
alreadi
avail
recent
effort
global
vaccin
coverag
eg
epi
gavi
face
increas
shortag
vaccin
suppli
caus
lack
industri
interest
problem
true
develop
countri
greatli
exacerb
poorest
countri
financi
capac
meet
cost
vaccin
howev
decreas
vaccin
price
countri
offer
reason
solut
price
could
alway
high
compani
increasingli
discourag
maintain
vaccin
busi
moreov
vaccin
develop
test
develop
countri
might
need
adapt
wide
differ
geograph
condit
infrastructur
present
countri
make
simpl
exampl
vaccin
need
conserv
c
may
pose
insurmount
difficulti
distribut
subequatori
countri
vaccin
need
multipl
administr
face
problem
complianc
inject
vaccin
pose
problem
suppli
steril
syring
safe
dispos
avoid
spread
infect
oral
nasal
vaccin
face
problem
proper
absorpt
popul
stricken
diarrhoeal
lung
diseas
generalis
mucos
inflamm
abund
mucu
secret
develop
new
vaccin
progress
slowli
point
view
basic
research
enthusiast
avail
fund
chariti
privat
organis
make
possibl
invest
also
area
consid
low
prioriti
develop
countri
case
intern
vaccin
institut
ivi
intern
organis
locat
south
korea
reli
upon
substanti
fund
receiv
gavi
run
toplevel
basic
research
epidemiolog
studi
vaccin
diarrhoeal
diseas
eg
shigella
rotavirus
run
larg
train
programm
asian
countri
bangladesh
china
india
pakistan
philippin
thailand
vietnam
main
problem
devis
effect
new
vaccin
adequ
vaccin
manufactur
proper
vaccin
distribut
administr
point
view
tendenc
intern
organis
support
independ
develop
vaccin
product
distribut
countri
issu
bother
vaccin
compani
fear
unforeseen
competit
risk
littl
possibl
enforc
patent
right
without
rais
strong
public
reaction
risk
generalis
damag
busi
howev
appear
consist
immin
risk
compani
inde
implement
independ
vaccin
product
lessdevelop
countri
need
basic
longterm
strategi
support
social
econom
develop
countri
social
econom
develop
necessari
industri
initi
independ
vaccin
manufactur
could
safe
establish
organis
human
frontier
scienc
programm
organis
hfspo
wellcom
trust
thirdworld
academi
scienc
twa
european
molecular
biolog
organis
embo
activ
tackl
issu
higher
educ
basic
research
life
scienc
lessdevelop
countri
although
appar
littl
immedi
practic
outcom
establish
higher
educ
programm
countri
format
class
young
independ
scientist
basi
futur
social
econom
develop
specif
train
technolog
transfer
need
order
implement
independ
vaccin
manufactur
distribut
sens
involv
vaccin
compani
basi
intern
cooper
licens
agreement
would
great
import
initi
ivi
move
direct
establish
facil
smallscal
vaccin
product
devot
train
thirdworld
personnel
technolog
transfer
coordin
intern
polici
forg
new
treati
implement
develop
poor
countri
basi
success
outcom
global
vaccin
health
improv
usa
polici
vaccin
undergon
major
chang
direct
septemb
due
threat
bioterror
larg
financi
resourc
contract
vaccin
compani
resumingincreas
product
old
vaccin
eg
anthrax
smallpox
spite
inadequ
safeti
profil
addit
larg
financi
support
research
made
avail
scientist
worldwid
three
area
biodef
vaccin
research
tackl
innat
adapt
immun
human
immunolog
unusu
suscept
civilian
popul
children
elderli
immunosuppress
peopl
eu
commiss
hand
focuss
effort
vaccin
field
new
framework
programm
almost
exclus
deal
three
major
povertyrel
diseas
viral
one
hivaid
bacteri
one
tuberculosi
tb
protozoan
one
malaria
programm
promot
intern
collabor
direct
involv
thirdworld
scientist
major
involv
vaccin
compani
r
activ
strong
train
programm
young
investig
develop
countri
wealth
initi
taken
individu
countri
eg
countri
northern
europ
sweden
denmark
furthermor
intern
organis
vaccin
programm
povertystricken
countri
unicef
ivi
larg
small
initi
worldwid
flourish
given
excel
social
percept
vaccin
tool
improv
human
health
advanc
social
econom
develop
consequ
privat
foundat
chariti
sustain
mani
initi
case
vaccin
fund
gavi
howev
progress
basic
research
vaccin
strategi
need
pursu
parallel
concomit
progress
industri
develop
manufactur
activ
practic
progress
take
place
current
shortag
vaccin
suppli
due
lack
industri
interest
overcom
industri
invest
new
vaccin
develop
implement
tabl
within
new
framework
programm
eu
commiss
specif
aim
povertyrel
diseas
follow
concept
improv
health
way
fight
poverti
specif
line
research
fund
entitl
confront
major
communic
diseas
link
poverti
strateg
object
action
develop
new
vaccin
drug
innov
intervent
fight
three
major
infecti
diseas
link
poverti
hivaid
malaria
tuberculosi
three
diseas
caus
consequ
poverti
mani
develop
countri
particular
subsaharan
africa
programm
action
acceler
action
hivaid
malaria
tuberculosi
context
poverti
reduct
eu
commiss
provid
broad
polici
framework
comprehens
global
multidisciplinari
approach
three
povertylink
diseas
concern
research
overal
strategi
develop
new
effect
intervent
three
diseas
order
realis
goal
action
organis
two
major
compon
develop
new
promis
candid
preclin
earli
human
test
phase
clinic
trial
ii
establish
clinic
trial
programm
support
phase
ii
iii
clinic
trial
plan
develop
new
effect
intervent
har
full
spectrum
basic
molecular
research
preclin
proofofprincipl
test
earli
human
test
safeti
trial
use
integr
differ
disciplin
approach
pursu
ration
systemat
concept
compar
evalu
procedur
emphasi
translat
new
knowledg
effect
develop
promis
new
candid
vaccin
drug
microbicid
involv
relev
research
group
develop
countri
highli
encourag
second
compon
action
implement
european
develop
countri
clinic
trial
partnership
edctp
one
main
goal
edctp
support
phase
ii
iii
clinic
trial
promis
candid
develop
countri
within
eu
polici
edctp
part
overal
strategi
independ
legal
financi
entiti
specif
dedic
support
clinic
trial
develop
countri
thu
relev
effort
eu
commiss
put
emphasi
basic
research
strongli
encourag
transfer
scientif
result
practic
need
import
industri
involv
advanc
train
activ
emphasis
essenti
compon
project
specif
direct
profession
develop
thirdworld
fellow
implement
format
research
basic
scienc
clinic
research
research
manag
industri
execut
user
knowledg
produc
within
project
first
approach
strategi
design
innov
vaccin
understand
path
interact
pathogen
host
cell
interact
dynam
pathogen
host
cell
upon
encount
chang
physiolog
featur
attempt
surviv
escap
mechan
pathogen
host
mechan
defenc
evolv
concomitantli
astonishingli
dynam
relationship
coevolut
reciproc
adapt
know
mechan
escap
built
pathogen
mechan
defenc
use
host
basi
design
effect
better
target
intervent
protect
innat
mechan
use
host
cell
fight
neutralis
pathogen
invas
mechan
use
microorgan
escap
host
surveil
comprehens
describ
excel
review
basset
et
al
first
interact
pathogen
host
usual
take
place
mucos
level
sinc
mucos
line
repres
mechan
barrier
extern
environ
intern
space
thu
first
defens
activ
take
place
mucos
surfac
avoid
adhes
microorgan
cell
surfac
cilial
movement
mucu
secret
epitheli
cell
also
express
defenc
receptor
eg
tolllik
receptor
tlr
recognis
bind
specif
pathogen
associ
molecular
pattern
pamp
initi
defens
cell
activ
epitheli
cell
synthesis
secret
wide
array
antimicrobi
peptid
includ
defensin
cathelicidin
histatin
contribut
host
defenc
cell
activ
lead
product
chemokin
cytokin
agent
signal
cell
injuri
chemokin
role
attract
immun
cell
neutrophil
macrophag
nk
cell
lymphocyt
infect
site
phagocyt
cell
neutrophil
macrophag
ingest
kill
microorgan
phagolysosom
cytokin
produc
infect
site
togeth
tlr
trigger
microbi
endogen
agent
activ
immun
cell
better
effect
inflammatori
defenc
action
initi
trigger
specif
acquir
immun
factor
potent
antimicrobi
role
produc
inflammatori
reaction
includ
cytokin
chemokin
acut
phase
protein
long
pentraxin
complement
compon
dendrit
cell
nk
cell
also
involv
pathogen
recognit
antigen
uptak
present
cytocid
activ
contribut
innat
defenc
respons
initi
subsequ
acquir
type
specif
immun
establish
immunolog
memori
microorgan
attach
epitheli
cell
specialis
surfac
structur
adhesin
receptor
avoid
recognit
tlr
antimicrobi
peptid
action
sever
pathogen
evolv
modif
surfac
compon
devis
inhibitori
molecul
defensin
pass
epitheli
barrier
microorgan
either
damag
induct
cell
necrosi
apoptosi
degrad
extracellular
matrix
invad
mucos
cell
enter
cell
microorgan
surviv
membranelink
vacuol
spread
underli
surround
tissu
surviv
innat
immun
surveil
microorgan
devis
system
inhibit
phagocytemedi
kill
differ
mechan
avoid
eg
interf
uptak
inhibit
phagolysosom
format
infect
agent
eg
virus
abl
produc
anticytokin
protein
mimic
solubl
cytokin
receptor
captur
neutralis
cytokin
thu
avoid
activ
immun
respons
last
two
decad
thought
vaccin
administ
via
oral
nasal
vagin
rectal
rout
ie
mucos
vaccin
could
solv
mani
problem
relat
parenter
vaccin
interest
develop
mucos
vaccin
base
seri
consider
first
place
establish
protect
immun
mucos
site
would
greatli
increas
vaccin
effect
light
fact
vast
major
infect
occur
begin
mucos
surfac
moreov
mucos
immunis
could
overcom
problem
vaccin
efficaci
immunosuppress
peopl
eg
hivinfect
peopl
previous
vaccin
parenter
vaccin
young
children
circul
matern
antibodi
practic
reason
easi
administr
highli
reduc
risk
transmit
infect
syring
case
inject
vaccin
sinc
experiment
model
mucos
vaccin
show
promis
result
expect
within
shorttim
mucos
vaccin
could
develop
human
use
howev
case
last
year
import
oral
vaccin
attenu
antipolio
vaccin
develop
sabin
progress
abandon
develop
countri
avoid
case
diseas
caus
vaccin
furthermor
two
recent
develop
mucos
vaccin
human
use
rotaviru
diarrhoea
influenza
withdrawn
short
period
market
advers
reaction
among
vaccine
howev
first
evid
nasal
vaccin
flu
mucos
adjuv
could
safe
effect
human
present
meet
extrem
import
develop
mucos
vaccin
would
paramount
import
erad
diseas
develop
countri
first
paradigm
immun
versu
toler
particularli
import
gastrointestin
level
must
solv
gastrointestin
toler
allow
us
coexist
normal
flora
ingest
larg
amount
foreign
food
protein
without
induc
harm
system
immun
respons
want
immunis
mucos
level
invent
new
deliveri
system
effect
mucos
adjuv
characterist
mucos
immun
system
differ
system
immun
respons
exploit
design
effect
mucos
vaccin
mucos
immun
system
mucos
associ
lymphoid
system
malt
well
defin
term
induct
effector
site
gastrointestin
tract
galt
nasal
tract
nalt
less
known
correspond
genitorect
associ
lymphoid
system
geralt
induct
site
region
lymph
node
aggreg
lymphoid
tissu
eg
peyer
patch
gut
immunis
occur
lymphocyt
migrat
effector
site
eg
mucos
lamina
propria
malt
common
commun
system
instanc
genit
mucos
immun
induc
nasal
oral
immunis
defenc
mucos
level
includ
mechan
innat
mechan
effect
epitheli
cell
innat
adapt
immun
involv
leukocyt
dendrit
cell
lymphocyt
secretori
iga
produc
mucos
surfac
particip
kill
invad
microorgan
opsonis
neutrophil
activ
arm
intestin
lymphocyt
antibodydepend
cellular
cytotox
mechan
inhibit
microbi
adhes
rout
featur
antigen
interact
immun
cell
mucos
surfac
determin
type
immun
respons
elicit
wherea
mucos
deliveri
microbi
antigen
eg
cholera
elicit
signific
respons
also
immunosuppress
patient
particular
characterist
mucos
system
induct
toler
especi
tdepend
antigen
abl
elicit
delay
type
hypersensit
reaction
dth
phenomenon
oral
toler
ignor
import
physiolog
mechan
avoid
develop
dth
allerg
reaction
ingest
food
protein
antigen
oral
toler
induct
mucos
immun
usual
involv
differ
type
antigen
oral
toler
difficult
imposs
induc
strong
immunogen
revers
true
mucos
immun
respons
howev
two
phenomena
mutual
exclus
sometim
mucos
immunis
procedur
may
concomitantli
give
rise
local
signific
iga
antibodi
format
toler
suppress
peripher
immun
respons
therefor
mucos
immunis
induct
oral
toler
may
repres
promis
approach
induc
protect
mucos
infecti
agent
system
inflammatori
autoimmun
disord
respect
howev
practic
difficult
elicit
strong
protect
immun
respons
iga
product
oral
administr
solubl
antigen
success
oral
vaccin
human
use
therefor
sabin
polio
vaccin
two
cholera
vaccin
one
kill
one
attenu
adenoviru
vaccin
thypoid
vaccin
overcom
difficulti
induc
effect
protect
immun
mucos
administr
antigen
differ
vector
studi
appropri
deliveri
mucos
site
sever
live
bacteri
vector
develop
target
deliv
relev
antigen
mucos
site
either
base
attenu
mutat
pathogen
eg
salmonella
shigella
bcg
bordetella
commens
bacteria
lactobacilli
certain
streptococci
staphylococci
tropism
bacteria
human
gut
respiratori
mucosa
essenti
adequ
deliveri
mucos
site
system
use
bacillu
spore
express
recombin
foreign
antigen
prove
effect
safe
induc
mucos
immun
protect
experiment
model
use
attenu
bacteri
vector
test
sever
infect
intracellular
pathogen
listeria
monocytogen
exploit
pathway
infect
follow
virul
bacterium
among
viral
vector
earli
vaccinia
vector
replac
poxvirus
eg
canari
poxviru
adenovirus
psudovirus
appear
rather
promis
viruslik
particl
vlp
recombin
selfassembl
nonrepl
viral
core
structur
nonenvelop
virus
high
immunogen
togeth
possibl
express
recombin
antigen
surfac
make
vlp
excel
candid
mucos
vaccin
deliveri
addit
vlp
prepar
pathogen
virus
use
safe
administ
natur
rout
infect
elicit
mucos
immun
iga
antibodi
vector
besid
actual
antigen
deliveri
serv
also
function
adjuv
usual
elicit
strong
activ
innat
respons
mechan
immunostimulatori
cytokin
product
experiment
system
effect
well
studi
mucos
adjuv
cholera
toxin
ct
close
relat
e
coli
heat
labil
enterotoxin
lt
toxin
pentam
cellbind
b
subunit
associ
singl
toxic
subunit
ct
lt
potent
enhanc
immunogen
mucos
level
increas
antigen
uptak
present
induc
b
cell
matur
immunostimulatori
cytokin
product
moreov
ct
lt
fail
induc
toler
even
abrog
toler
induct
howev
toxic
prevent
possibl
human
use
develop
nontox
ct
lt
deriv
first
base
isol
b
subunit
ctb
ltb
howev
work
physic
coupl
antigen
deliv
intranas
nontox
recombin
mutat
form
ct
lt
retain
partial
adjuv
capac
compar
nativ
toxin
mutant
modif
subunit
ct
cta
also
test
promis
result
although
gener
adjuvant
decreas
toxic
agent
stimul
innat
immun
trigger
tolllik
receptor
excel
adjuv
induc
product
cytokin
costimulatori
molecul
contribut
nonspecif
amplif
immun
respons
also
induct
specif
adapt
immun
agent
essenti
microbi
product
abl
induc
strong
inflamm
eg
bacteri
lp
howev
particular
interest
potenti
adjuv
synthet
oligodeoxynucleotid
contain
nonmethyl
cytosinephosphateguanosin
cpg
motif
particularli
abund
bacteri
dna
cpg
motif
bind
trigger
strong
predominantli
immun
respons
cytokin
product
cpg
oligodeoxynucleotid
besid
good
system
adjuv
quit
effect
also
mucos
adjuv
sever
experiment
system
intranas
oral
vagin
administr
cpg
oligodeoxynucleotid
togeth
antigen
induc
mucos
iga
product
system
respons
cytokin
product
cytotox
lymphocyt
ctl
induct
effect
protect
subsequ
infecti
challeng
sinc
signific
part
effect
mani
adjuv
due
induct
inflammatori
cytokin
combin
cytokin
test
obtain
adjuv
effect
absenc
toxic
well
known
potent
adjuv
activ
combin
cytokin
particular
elicit
mucos
immun
respons
ctl
iga
antigen
potent
obtain
ct
use
chemokin
also
proven
use
stimul
effect
mucos
immun
mucos
administr
antigen
experiment
model
although
thorough
studi
efficaci
chemokin
mucos
adjuv
avail
one
great
advantag
mucos
vaccin
pathogen
exploit
rout
use
pathogen
enter
invad
bodi
mucos
vaccin
therefor
take
advantag
mucos
rout
elicit
type
defens
reaction
mount
pathogen
innat
local
reaction
subsequ
specif
local
system
immun
gener
memori
ie
optim
respons
pathogen
togeth
peculiar
featur
commun
mucos
associ
lymphoid
system
make
mucos
vaccin
choic
vaccin
infect
occur
begin
mucos
surfac
account
major
infecti
diseas
notion
health
necessari
econom
social
progress
nation
given
rise
numer
privat
public
initi
worldwid
improv
health
condit
develop
countri
vaccin
first
object
tackl
need
renew
effort
develop
novel
vaccin
make
old
vaccin
avail
end
global
strategi
support
vaccin
busi
design
order
attract
interest
industri
would
ensur
adequ
suppli
vaccin
develop
develop
countri
would
also
encourag
new
invest
research
vaccin
field
special
emphasi
also
devot
support
higher
educ
train
research
basic
scienc
develop
countri
pose
basi
futur
independ
develop
thu
allow
implement
technolog
transfer
independ
vaccin
product
manufactur
distribut
need
vaccin
develop
countri
implement
sever
parallel
strategi
reestablish
product
old
vaccin
implement
nation
polici
vaccin
support
research
develop
new
vaccin
eg
aid
optimis
old
vaccin
increas
efficaci
safeti
eg
new
rout
administr
need
vaccin
develop
countri
dealt
differ
object
immedi
use
old
vaccin
even
efficaci
complet
reduc
diseas
burden
research
develop
tailor
vaccin
adapt
differ
condit
popul
health
state
consid
ongo
infect
andor
mucos
inflamm
eg
diarrhoea
respiratori
infect
immunodepress
condit
starvat
diseas
age
newborn
young
children
elderli
peopl
geograph
consider
climat
genet
factor
mucos
vaccin
one
promis
avenu
futur
vaccin
advantag
includ
high
efficaci
due
exploit
routesmechan
immun
activ
infect
microorgan
effect
also
immunosuppress
peopl
presenc
interf
immun
easi
administr
low
crossinfect
risk
despit
limit
success
obtain
far
develop
mucos
vaccin
human
use
ongo
futur
research
effort
direct
bound
yield
import
result
fight
diseas
poverti
